Department of General Practice and Nursing Science, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
Department of Epidemiology and Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Open Heart. 2023 Nov 28;10(2):e002501. doi: 10.1136/openhrt-2023-002501.
Literature supports associations between common respiratory tract infections (RTIs) and risk of cardiovascular diseases, yet the importance of RTIs for cardiovascular risk management remains less understood. This systematic review and meta-analysis aimed to estimate the causal effects of RTIs on occurrence of cardiovascular diseases in the general population.
MEDLINE and EMBASE were systematically searched up to 4 November 2022. Eligible were all aetiological studies evaluating risk of cardiovascular outcomes after exposure to common RTIs within any follow-up duration. Evidence was pooled using random-effects models if data allowed. The ROBINS-E and GRADE approaches were used to rate risk of bias and certainty of evidence, respectively. All assessments were performed in duplicate.
We included 34 studies (65 678 650 individuals). Most studies had a high risk of bias. COVID-19 likely increases relative risk (RR (95% CI)) of myocardial infarction (3.3 (1.0 to 11.0)), stroke (3.5 (1.2 to 10)), pulmonary embolism (24.6 (13.5 to 44.9)) and deep venous thrombosis (7.8 (4.3 to 14.4)) within 30 days after infection (GRADE: moderate) and about twofold within 1 year (GRADE: low to moderate). Other RTIs also likely increase the RR of myocardial infarction (2.9 (95% CI 1.8 to 4.9)) and stroke (2.6 (95% CI 1.1 to 6.4)) within 30 days (GRADE: moderate), and to a lesser extent with longer follow-up.
RTIs likely increase the risk of cardiovascular diseases about 1.5-5 fold within 1 month after infection. RTIs may, therefore, have clinical relevance as target for cardiovascular risk management, especially in high-risk populations.
CRD42023416277.
文献支持常见呼吸道感染(RTIs)与心血管疾病风险之间的关联,但 RTIs 对心血管风险管理的重要性仍知之甚少。本系统评价和荟萃分析旨在估计 RTIs 对普通人群心血管疾病发生的因果影响。
系统检索了 MEDLINE 和 EMBASE 数据库,截至 2022 年 11 月 4 日。所有病因研究均符合条件,这些研究评估了在任何随访时间内暴露于常见 RTIs 后发生心血管结局的风险。如果数据允许,使用随机效应模型汇总证据。使用 ROBINS-E 和 GRADE 方法分别评估偏倚风险和证据确定性。所有评估均由两人进行。
我们纳入了 34 项研究(65678650 人)。大多数研究存在高偏倚风险。COVID-19 可能会增加感染后 30 天内心肌梗死(3.3(1.0 至 11.0))、中风(3.5(1.2 至 10))、肺栓塞(24.6(13.5 至 44.9))和深静脉血栓形成(7.8(4.3 至 14.4))的相对风险(RR(95%CI))(GRADE:中度),在 1 年内约增加两倍(GRADE:低至中度)。其他 RTIs 也可能在 30 天内增加心肌梗死(2.9(95%CI 1.8 至 4.9))和中风(2.6(95%CI 1.1 至 6.4))的 RR(GRADE:中度),并且在随访时间较长时,RR 降低。
RTIs 可能会在感染后 1 个月内使心血管疾病的风险增加 1.5-5 倍。因此,RTIs 可能具有临床相关性,可作为心血管风险管理的目标,特别是在高危人群中。
PROSPERO 注册号:CRD42023416277。